Colorectal Adenocarcinoma Metastatic in the LiverNCT07569341
Validation of the Classification for Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases
An observational study of Colorectal Adenocarcinoma Metastatic in the Liver, run by University Hospital, Linkoeping at 1 site in Sweden.
Trial summary
The aim of this study is to validate a proposed classification system regarding overall survival as well as a comparison with patients with liver metastases and extrahepatic metastasis of colorectal cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Adenocarcinoma Metastatic in the Liver
- What is being tested?
- Liver resection
- Type of treatment
- Surgery or procedure
- How many people
- 116 participants
- Where
- 1 siteSweden
- Study dates
- 1 Nov 2021to 1 Apr 2026
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients with colorectal liver metastases assessed at multidisciplinary team conferences in Linköping University Hospital 2021-11-01 -- 2022-12-31
Who may be able to join
- Colorectal liver metastasis.
- Discussed at a multidisciplinary tumor board
Who cannot join
- Age less than 18 years.
- Previous cancer in the gastrointestinal tract
- Ongoing oncological treatment for cancers other than gastrointestinal cancers
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this study is to validate a proposed classification system regarding overall survival as well as a comparison with patients with liver metastases and extrahepatic metastasis of colorectal cancer. The study also aims to identify the proportion of patients in each group, the proportion of patients converted from 4c to 4b and to compare survival to the patients only treated with chemotherapy.
- Being tested
- Liver resection
- Keywords
- Colorectal liver metastasis, classification
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liver resectionProcedure or surgery
Removal or destruction of liver tumors
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start1 Nov 2021
- Primary completion1 Apr 2026
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Adenocarcinoma Metastatic in the LiverStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 116 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- University Hospital, Linkoeping
- Sponsor type
- University, hospital or other
- Collaborators
- Linkoeping University
- Responsible party
- Principal investigator, Per Sandström, University Hospital, Linkoeping
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07569341
- Sponsor's protocol ID
- Classification of CRLM
- Status last verified
- Apr 2026
- First submitted
- 29 Apr 2026
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of the Classification for Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases
- ClinicalTrials.gov ID
- NCT07569341
- Acronym / sponsor ID
- Classification of CRLM
- Keywords
- Colorectal liver metastasis, classification
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 116 participants (actual)
- Lead sponsor
- University Hospital, LinkoepingUniversity, hospital or other
- Collaborators
- Linkoeping University
- Study start
- 1 Nov 2021 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 6 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to validate a proposed classification system regarding overall survival as well as a comparison with patients with liver metastases and extrahepatic metastasis of colorectal cancer. The study also aims to identify the proportion of patients in each group, the proportion of patients converted from 4c to 4b and to compare survival to the patients only treated with chemotherapy.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 3 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients with colorectal liver metastases assessed at multidisciplinary team conferences in Linköping University Hospital 2021-11-01 -- 2022-12-31
Key inclusion criteria (2 listed)
- Colorectal liver metastasis.
- Discussed at a multidisciplinary tumor board
Key exclusion criteria (3 listed)
- Age less than 18 years.
- Previous cancer in the gastrointestinal tract
- Ongoing oncological treatment for cancers other than gastrointestinal cancers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liver resectionRemoval or destruction of liver tumors | Procedure or surgery | – |
Primary outcome
Overall survival
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Colorectal Adenocarcinoma Metastatic in the Liver
RecruitingPhase 1/2
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
RecruitingPhase 2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
RecruitingPhase 2
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Colorectal Adenocarcinoma Metastatic in the Liver
RecruitingPhase 2
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Adenocarcinoma Metastatic in the Liver, run by University Hospital, Linkoeping at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.